Format

Send to

Choose Destination
MMWR Morb Mortal Wkly Rep. 2010 Mar 19;59(10):299.

Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.

Abstract

CDC announces the availability of a new heptavalent botulinum antitoxin (HBAT, Cangene Corporation) through a CDC-sponsored Food and Drug Administration (FDA) Investigational New Drug (IND) protocol. HBAT replaces a licensed bivalent botulinum antitoxin AB and an investigational monovalent botulinum antitoxin E (BAT-AB and BAT-E, Sanofi Pasteur) with expiration of these products on March 12, 2010. As of March 13, 2010, HBAT became the only botulinum antitoxin available in the United States for naturally occurring noninfant botulism.

PMID:
20300057
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for CDC - Morbidity and Mortality Weekly Report
Loading ...
Support Center